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Background: Even though more than 600 stroke treatments have been shown effective in preclinical studies,
clinically proven treatment alternatives for cerebral infarction remain scarce. Amongst the reasons for the
discrepancy may be methodological shortcomings, such as high mortality and outcome variability, in the preclinical
studies. A common approach in animal stroke experiments is that A) focal cerebral ischemia is inflicted, B) some
type of treatment is administered and C) the infarct sizes are assessed. However, within this paradigm, the
researcher has to make numerous methodological decisions, including choosing rat strain and type of surgical
procedure. Even though a few studies have attempted to address the questions experimentally, a lack of consensus
regarding the optimal methodology remains.
Methods: We therefore meta-analyzed data from 502 control groups described in 346 articles to find out how rat
strain, procedure for causing focal cerebral ischemia and the type of filament coating affected mortality and infarct
size variability.
Results: The Wistar strain and intraluminal filament procedure using a silicone coated filament was found optimal
in lowering infarct size variability. The direct and endothelin methods rendered lower mortality rate, whereas the
embolus method increased it compared to the filament method.
Conclusions: The current article provides means for researchers to adjust their middle cerebral artery occlusion
(MCAo) protocols to minimize infarct size variability and mortality.
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Ischemic stroke is amongst the leading causes of death
and disability in the world and has been the subject of
massive research efforts during recent years. Even though
these efforts have resulted in more than 600 treatments
reported effective in preclinical studies [1], clinically
proven treatment options are still few. There are reasons
to believe that this apparent translational roadblock may
inter-alia be due to methodological confounding factors,
including high mortality and large outcome variability, in
the preclinical studies [2-4].
The usual approach in experimental stroke studies,
used in hundreds of publications each year, is that A)
focal cerebral ischemia is inflicted in rodents [5,6], B)* Correspondence: jakob.strom@liu.se
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reproduction in any medium, provided the orsome type of treatment is administered and C) the in-
farct sizes are assessed. Even though this setup may
seem straight forward, there are infinite numbers of
methodological variants, and there is a profound lack of
consensus regarding the ideal methodology to be used in
experiments of this kind. A small number of studies
aiming to optimize the infarct induction regarding the
important aspects of mortality and variability, for ex-
ample by testing various rodent strains and sizes [7-9],
surgical procedures [10-13] or occluding intraluminal fil-
aments [14], have been published. However, these stud-
ies have rendered conflicting results, and are too few
and too small to provide comprehensive understanding
of how the different methodological parameters interact.
Hence, it was thought of interest to investigate the in-
fluence of different methodological factors on infarct
variability and mortality in rat stroke models using a
hypothesis-driven meta-analytical approach where theirtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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than disregarded. The meta-analytical approach seemed
attractive since such a vast number of studies with the
abovementioned experimental setup are published, and
since control/vehicle/placebo groups (hereby referred to
as “control groups”), suitable for inter-study compari-
sons, are almost invariably included. A study of this kind
has, to the best of our knowledge, not been published
previously. Even though other animals, not least mice,
are also well-used in experimental stroke research, rats
were due to space restrictions chosen to be the sole
focus of the current article.
The aim of the current meta-analysis was to investigate
chosen methodological variables’ effects on infarct size
variability and mortality. An a priori hypothesis of six
main factor-outcome relations (1A-3B) was established:
1. Rat strain affects (A) infarct size variability and (B)
mortality.
2. Type of focal ischemia procedure affects (A) infarct
size variability and (B) mortality.
3. In studies using the intraluminal filament method,




To identify articles to be included in the meta-analysis,
Medline was searched with the line (mcao or “middle
cerebral artery occlusion” or “MCA occlusion” or “stroke”
or “cerebral ischemia” or “brain ischemia”) and (rat or
rats), resulting in more than 19,000 hits. Starting with
the latest article the 10th of June 2011 [15], the articles
were consecutively, in order of PubMed identifier,
assessed for inclusion in the study.
The inclusion criteria were:
A. Article written in English
B. Original research article
C. Experiments performed in living adolescent, adult or
elderly rats
D. Animals inflicted one single focal cerebral ischemic
lesion
E. Infarct size assessed and results presented
F. Inclusion of a control group, untreated except for
vehicle treatments
G. Sufficient description of fundamental aspects of the
experiment (after e-mail correspondence)
Data extraction
Data about the control groups were extracted from all
included articles. If an article included more than one
control group, differing in for example euthanasia time-
point, all control groups were separately included andassessed independently of each other. When extracting
the method data, we adhered strictly to the principle “If
it is not described, it was not performed”. Registered fac-
tors and outcome measures are listed in Table 1.
Because many of the included articles/control groups
lacked information about for example mortality rate, the
researchers of those articles were contacted via e-mail
with a gentle request to provide this information. In
total, the authors of 310 articles were e-mailed, of which
183 (59%) complied.
Since power calculations for large multiple regression
analyses are extremely complex to perform a priori, a sat-
uration principle was adopted to determine a sufficient
number of control groups to be included. After informa-
tion from 300 control groups had been extracted, an in-
terim analysis was performed, and then re-performed
every 40–50 new control groups included. When the re-
sults had stabilized (no changes in overall trends, and only
minor changes in p-values), no more articles were in-
cluded. 502 control groups from 346 articles were finally




After extraction of data, categories represented by less
than 5 control groups (corresponding to less than 1% of
the material) were included in the Others-categories.
This approach was motivated by the fact that these small
categories otherwise would run the risk of being attrib-
uted high explanatory values that were not statistically
substantiated, thus obscuring the influence of other
categories.
In the Other strain category, the following variants
were included: Long Evans rats, T-cell deficient nude
rats, SHRSP, Fischer rats, Zucker rats, Hooded Wistar
rats, Lewis rats, Holtzmann rats and Swiss albino rats.
The variable Sex finally contained four categories,
since males formed the first category, females that were
not explicitly ovariectomized were separated from ovari-
ectomized females in a second and third category, and
control groups using mixed or unspecified animals were
grouped in a fourth category.
Fifteen various anesthesia regimens were reduced to
four main categories and one Others category (in which
for example methohexithal sodium, medetomedin and un-
specified regimens were included). All inhalation anes-
thetics (isoflurane, halothane, sevoflurane, fluothane and
enflurane) were included in the first category, while
chloral hydrate was used frequently enough (and was not
appreciably similar to any other category) to deserve a cat-
egory of its own. The third category, Ketamine, included
all ketamine containing regimens, such as ketamine/
xylazine, ketamine/rumpun or ketamine only. Finally, all
Table 1 Extracted factors and outcome measures










Sex Category I. Male Male
II. Female
III. Ovx female
IV. Mix or not specified
Elderly rats ** Category, Binomial [No] [No]
[Yes]
Weight Continuous Grams NA
Animal exclusion rate Continuous % NA
Anesthesia factors
Type of anesthetic Category I. Inhalation anesthetic Inhalation anesthetic
II. Chloral hydrate
III. Ketamine
IV. Barbiturates and benzodiazepines
V. Other anesthetics
Intubation Category, Binomial [No] [No]
[Yes]
Awakening of rats during occlusion Category, Binomial [No] [No]
[Yes]
Temperature feedback system Category, Binomial [No] [No]
[Yes]
Electroencephalographic surveillance Category, Binomial [No] [No]
[Yes]
Blood pressure monitored Category, Binomial [No] [No]
[Yes]
Heart rate monitored Category, Binomial [No] [No]
[Yes]




Category, Binomial [No] [No]
[Yes]
Blood glucose concentration analyzed Category, Binomial [No] [No]
[Yes]
Postoperative antibiotics Category, Binomial [No] [No]
[Yes]
Focal ischemia procedure factors
Type of middle cerebral artery
occlusion procedure
Category I. Intraluminal filament Intraluminal filament
II. Direct, mechanical***
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Occlusion duration**** Category I. Short transient (up to 60 minutes) Short transient (up to
60 minutes)
II. Long transient (>60 min)
III. Permanent
Occluding filament type (Only studies
using the intraluminal filament method)





Time after focal ischemia for evaluation
of damage
Continuous Hours NA
Type of infarct size evaluation Category I. TTC TTC
II. Radiology
III. Acidic/Basic stain or silver
stain histology
IV. Immunohistology
Edema correction used Category, Binomial [No] [No]
[Yes]
Blinding of infarct size determination
procedure
Category, Binomial [No] [No]
[Yes]
Criteria for excluding rats Category I. None None
II. Observed absence of cerebral blood
flow reduction
III. Lack of functional deficit
IV. Too small infarct
V. Other pathology in animal
Outcome measures
Infarct size coefficient of variation Continuous % NA
Mortality rate Continuous % NA
* Only categories represented by at least 5 control groups were included in the analysis to avoid statistically inadequate attribution of explanatory value to too
small categories. Categories represented by less than 5 control groups were in the analysis included in an Others category. Further, some other reductions in
number of categories were performed, as presented below.
** Elderly rats were defined as being >12 months of age at time of ischemic insult.
*** Direct, mechanical refers to all MCAo procedures where the MCA is mechanically occluded from the outside, for example by clips, cauterization or ligation.
**** Only methods including actions taken to ensure reperfusion (such as removing the occluding intraluminal filament or arterial clip) were considered transient.
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bensodiazepine groups, such as pentobarbital and diaze-
pam, formed a fourth category.
The variable Blood gases/O2 saturation analyzed was
initially registered as the separate variables Blood pH an-
alyzed, Blood oxygen saturation analyzed and Blood car-
bon dioxide analyzed, however these three were so
highly correlated that they were thought better to be
represented by only one variable.
Regarding the techniques for causing focal ischemic le-
sions, all intraluminal filament procedures were reduced
to one single category. All direct occlusion techniques,based on craniectomy followed by physical occlusion of
the MCA by means of a clip, suture, hook or cauterizer,
formed the Direct category, while emboli techniques
were clumped up in a third category. Photothrombotic
procedures and methods of endothelin injection defined
the fourth and fifth categories, respectively. It should
however be noted that the occlusion time was accounted
for in another variable and that the choice of different
filaments were analyzed separately.
The filament categories, used for the analyses addressing
hypotheses 3A and 3B, were also reduced. The uncoated
filaments, a seemingly homogenous group, formed the
D. Animals inflicted 









E. Infarct size assessed 
and results presented
N= 374




performed in living 
adolescent, adult or 
elderly rats
N= 1038
F.  Control group 
included
N= 370
B. Not original 
research article
N= 79
A. Article not written in
English
N= 84
C. Experiments not 
performed in living 
adolescent, adult or 
elderly rats
N= 229
D. Animals not 











F.  Control group not 
included
N=4 
G. Not adequately 
described experiment
N= 24
E. Infarct size not 
assessed or results not 
presented 
N= 229
Number of Control  
groups to be included in 
at least one of the 
analyses: 502
Lacking data for 
analysis 3B
N groups: 237
Finally included i 
analysis 3B
N groups: 265
Lacking data for 
analysis 3A
N groups: 119
Finally included i 
analysis 3A
N groups: 383
Lacking data for 
analysis 1B and 2B
N groups: 151
Finally included i 
analysis 1B and 2B
N groups: 351
Lacking data for 
analysis 1A and 2A
N groups: 33
Finally included i 
analysis 1A and 2A
N groups: 469
Figure 1 When analyses were saturated, 1430 articles had been evaluated for inclusion in the meta-analysis. After exclusion due to
criteria A-G, 346 studies, describing 502 control groups, remained. Due to lack of certain pieces of information in some of the articles, not all 502
control groups could be included in all four multiple regression analyses, as shown in the thick-boarded boxes to the right in the figure.
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the Silicone category. Poly-L-Lysine formed a category of
its own, while other rare coating techniques (including for
example heparin coating, “glue coating” and paraffin coat-
ing) were put in a separate category together with un-
specified coating techniques.
The procedures used for infarct evaluation were reduced
to four categories. The most frequently used technique,
2,3,5-triphenyltetrazolium chloride staining, defined the first
category, while radiologic methods (in the majority of cases
magnetic resonance imaging, but in a few cases computed
tomography) were put in a Radiology category. Various
acidic/basic staining techniques (such as hematoxylin/eosin,cresyl violet and thionine) was, together with silver staining
(used in only one of the included studies), included in cat-
egory number three, while immunohistological methods
were put in a fourth category.
Edema correction can be performed in different ways
[360,361]. It was initially the intention to register not
only if, but also which type of, edema correction was
used. However, it soon turned out that this was not spe-
cified in a sufficient number of articles to perform a
meaningful analysis. It was therefore only registered if
edema correction had been used or not.
Concerning the exclusion procedures, the first cat-
egory included all control groups in which no exclusion
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control groups in which surveillance of blood flow re-
duction (for example using laser-doppler), with the
plausible aim to exclude the absence of such, were put.
The third, fourth and fifth categories contained control
groups from articles in which lack of functional deficit,
too small infarct size or other pathology (including intra-
cerebral hemorrhage), respectively, were stated to be ex-
clusion criteria. It should be noted that control groups
from articles accounting for multiple exclusion criteria
were registered in more than one of the exclusion
categories.
Definition of continuous variables
Animal exclusion rate was defined as the percentage of
rats excluded due to other reasons than mortality from
induction of focal cerebral ischemia until the final infarct
size assessment. Time after focal ischemia for evaluation
of damage was defined as the time from cerebral blood
flow obstruction until sacrifice. The outcome Infarct size
coefficient of variation was defined as the standard devi-
ation of the infarct volume divided by the average infarct
volume. Irrespective of how the infarct size is presented;
as percentage of the whole brain, as percentage of the
hemisphere or in cubic millimeters, this calculation pro-
vides a strictly defined, and inter-comparable, measure
of the infarct size variability. The other outcome, Mor-
tality, was defined as the unintended mortality in the
control group, from induction of focal cerebral ischemia
until infarct size assessment, as a percentage of the
whole group.
Statistical analyses
A priori, six main hypotheses (1A-3B) were put (as
aforementioned):
1. Rat strain affects (A) infarct size variability and (B)
mortality
2. Type of focal ischemia procedure affects (A) infarct
size variability and (B) mortality.
3. In studies using the intraluminal filament method,
the type of filament affects (A) infarct size variability
and (B) mortality.
Obviously, several additional hypotheses could be
tested in the information compiled from the studies, but
the higher number of hypotheses, the higher the risk of
finding falsely significant results due to multiple com-
parisons (type I errors). However, due to the risk of type
II-errors, corrections for multiple comparisons were not
performed, calling for separate assessment of the six
hypotheses.
All category variables were dummy-converted before
analysis (Table 1). For categorical variables with more thantwo categories, the most common category was chosen to
be the reference category. For binary variables, it does not
matter which one is made the reference, why [No] (in
other words, the lack of a specific methodological ingredi-
ent) was consistently chosen. The data were subsequently
analyzed using multiple regression analyses with backward
variable exclusion. This step identified which factors sig-
nificantly affected the outcomes Infarct size coefficient of
variation and Mortality, respectively. Next, an enter
model, in which the variables from the backward proced-
ure were complemented by lacking dummy variables, was
performed (the enter models with the variables found sig-
nificant in the backward analyses are presented in Tables 2,
3, 4, 5). The analyses were weighted according to the num-
ber of animals used in each group; hence, a study includ-
ing 5 animals in the control group was given less impact
than a study including 20 animals. In total, four large mul-
tiple regression models (one for hypotheses 1A and 2A,
one for hypotheses 1B and 2B, one for hypothesis 3A and
one for hypothesis 3B) were set up, testing the combined
effects of all available factors on the respective outcome
measure (Infarct size coefficient of variation or Mortality
rate). Hence, all models controlled for the factors listed in
Table 1 when testing the stated hypotheses. All statistical
calculations were performed in SPSS (Version 20, IBM
Corporation, Armonk, NY, USA). P-values <0.05 were con-
sidered statistically significant. Data were presented as
mean ± standard deviation or, when presenting results
from the meta-analysis, with 0.95 confidence interval
shown within brackets. It should be noted that the percent
changes (regression coefficients) in Infarct size coefficient of
variation and Mortality rate are presented in absolute, not
relative, terms. In other words, if a certain variable de-
creasesMortality rate with 10%, it means that the mortality
would decrease from for example 40% to 30%, and not
merely from 40% to 36%.
Protocol violations
It was originally planned to include the variable Exclu-
sion rate to control for this confounder; however, too
few articles presented the needed information. Even after
all persistent e-mail correspondence, such a high num-
ber of studies lacked this variable that including it would
have seriously hampered the analyses’ power. The vari-
able was therefore omitted.
Electroencephalographic surveillance was only utilized
in one of the included studies, and this variable could
thus not be analyzed. It was therefore omitted.
Results
Impact of rat strain on infarct size coefficient of variation
and mortality: Hypotheses 1A-B
Strain significantly affected both Infarct size coefficient of
variation and Mortality rate. Wistar had the strongest
Table 2 Regression formula for hypotheses 1A and 2A
Regression formula for the effect of Strain and Type of middle cerebral artery occlusion procedure on Infarct size coefficient of variation
(hypotheses 1A and 2A)





Constant NA 23.1 8.3 38.0 0.002
Strain (Sprague Dawley) Wistar −6.2 −11.5 −0.9 0.023
SHR −1.7 −11.0 7.5 0.710
WKY 19.0 −0.8 38.8 0.059
Other Strains 20.7 10.7 30.8 0.000
Type of middle cerebral artery occlusion
procedure (Intraluminal filament)
Direct, mechanical 4.2 −3.4 11.8 0.274
Embolic 14.7 3.4 26.0 0.011
Photothrombotic 10.1 −5.2 25.5 0.196
Endothelin injection 23.1 9.3 36.9 0.001
Sex (Male) Female −0.6 −19.7 18.5 0.951
Ovx female 2.3 −16.7 21.4 0.810
Mix or not specified −11.5 −21.5 −1.5 0.024
Elderly rats [Yes] −23.6 −39.6 −7.7 0.004
Weight [Continuous; Grams] 0.1 0.0 0.1 0.001
Type of anesthetic (Inhalation anesthetic) Chloral Hydrate −11.5 −16.9 −6.1 0.000
Ketamine 2.9 −4.4 10.2 0.430
Barbiturates and bensodiazepines −8.4 −17.6 0.9 0.076
Other anesthetic −13.6 −22.6 −4.6 0.003
Awakening of rats during occlusion (No) [Yes] 8.8 0.9 16.7 0.028
Temperature feedback system (No) [Yes] −6.9 −12.4 −1.5 0.013
Blood hemoglobin concentration analyzed (No) [Yes] 10.9 3.0 18.8 0.007
Occlusion duration (Short transient) Long transient 1.9 −3.9 7.8 0.519
Permanent −16.6 −24.1 −9.1 0.000
Time after focal ischemia for evaluation of
damage
[Continuous; Hours] 0.0051 0.0005 0.0096 0.030
Criteria for excluding rats (None) Observed absence of cerebral blood flow
reduction
−7.7 −12.4 −2.9 0.002
Lack of functional deficit −2.9 −8.6 2.7 0.310
Too small infarct 0.1 −9.6 9.9 0.981
Other pathology in animal 18.6 12.7 24.6 0.000
Variables excluded by statistical software due to too low explanatory value: Intubation, Postoperative antibiotics, Blood pressure monitoring, Heart rate
monitoring, Blood gases/O2 saturation analyzed, Blood glucose concentration analyzed, Type of infarct size evaluation, Edema correction used, Blinding of infarct
size determination procedure.
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lower variability (−6.2%, 0.95 CI: -11.5 to −0.9%, p = 0.023)
than the well-used Sprague Dawley, while the category
Other strains had significantly higher variability (+20.7%,
0.95 CI: +10.7 to +30.8%; p = 0.000; Figure 2; Table 2).
The only effect of Strain on Mortality rate was that SHR
seemed to render lower percentages (−6.9%, 0.95 CI: -12.8
to −0.87%; p = 0.025; Figure 2; Table 3).
The multiple regression analysis addressing hypotheses
1A and 2A included 469 control groups, while the ana-
lysis for hypotheses 1B and 2B included 351 control
groups (Figure 1). These regression formulae had r2 of0.34 and 0.31, respectively, meaning that they explained
34% and 31% of the variation in the outcomes Infarct
size coefficient of variation and Mortality rate.Impact of focal ischemia procedure on infarct size
coefficient of variation and mortality: Hypotheses 2A-B
Regarding Infarct size coefficient of variation, all analyzed
surgical procedures had positive regression coefficients, in-
dicating higher variability than in the intraluminal filament
method, here chosen to be the reference. This trend was
significant for the Emboli (+14.7%, 0.95 CI: +3.4 to +26.0%;
Table 3 Regression formula for hypotheses 1B and 2B
Regression formula for the effect of Strain and Type of middle cerebral artery occlusion procedure on Mortality rate (hypotheses 1B and 2B)
Variable (reference category) Variable categories Regression coefficient 0.95 confidence interval
for regression coefficient
p-value
Constant NA 17.1 13.9 20.3 0.000
Strain (Sprague Dawley) Wistar 1.0 −2.4 4.4 0.551
SHR −6.9 −12.8 -.87 0.025
WKY −8.3 −19.3 2.8 0.141
Other Strains 4.4 −1.1 9.9 0.113
Type of middle cerebral artery occlusion
procedure (Intraluminal filament)
Direct, mechanical −10.7 −15.1 −6.2 0.000
Embolic 12.1 6.9 17.3 0.000
Photothrombotic −5.6 −15.3 4.2 0.262
Endothelin injection −9.7 −16.8 −2.6 0.007
Type of anesthetic (Inhalation anesthetic) Chloral Hydrate 4.1 0.17 8.1 0.041
Ketamine 3.2 −1.1 7.4 0.144
Barbiturates and bensodiazepines 1.1 −4.6 6.8 0.710
Other anesthetic 3.0 −1.9 8.0 0.230
Awakening of rats during occlusion (No) [Yes] 9.1 3.9 14.2 0.001
Heart rate monitored (No) [Yes] −3.3 −7.5 0.94 0.127
Blood glucose concentration analyzed (No) [Yes] −2.8 −6.1 0.53 0.099
Type of infarct size evaluation (TTC) Radiology 5.4 −0.11 10.9 0.055
Acidic/Basic stain or silver stain histology −1.2 −4.7 2.4 0.526
Immunohistology 10.4 3.2 17.6 0.005
Criteria for excluding rats (None) Observed absence of cerebral
blood flow reduction
−4.0 −6.9 −1.1 0.008
Lack of functional deficit 0.15 −3.4 3.7 0.933
Too small infarct 0.22 −5.1 5.6 0.935
Other pathology in animal −3.4 −7.1 0.40 0.079
Variables excluded by statistical software due to too low explanatory value: Sex, Elderly rats, Weight, Intubation, Temperature feedback system, Blood pressure
monitored, Blood gases/O2 saturation analyzed, Blood hemoglobin concentration analyzed, Postoperative antibiotics, Occlusion duration, Time after focal ischemia
for evaluation of damage, Edema correction used, Blinding of infarct size determination procedure.
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p = 0.001) categories (Figure 3, Table 2).
The emboli (+12.1%, 0.95 CI: +6.9 to +17.3%; p = 0.000)
method rendered higher mortality than the intraluminal
filament method, while the direct (−10.7%, 0.95 CI: -15.1
to −6.2%; p = 0.000) and endothelin (−9.7%, 0.95 CI: -16.8
to −2.6%; p = 0.000) methods resulted in lower mortality
(Figure 3, Table 3).Impact of type of filament on infarct size coefficient of
variation and mortality: Hypotheses 3A-B
In studies in which the intraluminal filament method
had been used, silicone coating of the occluding filament
substantially and significantly lowered Infarct size coeffi-
cient of variation compared to uncoated filaments
(−12.7%, 0.95 CI: -18.3 to −7.0%; 0.000). It should alsobe noted that Poly-L-Lysine had a positive regression co-
efficient, indicating a slight trend of increased rather
than decreased variability in comparison with the refer-
ence category (Figure 4, Table 4).
The choice of filament coating had no significant ef-
fects on mortality, and regression coefficients were gen-
erally small (Figure 4, Table 5).
The multiple regression analyses addressing hypoth-
eses 3A and 3B included 383 and 265 control groups,
respectively, all using the intraluminal filament tech-
nique (Figure 1). These regression formulae had r2 of
0.40 and 0.27.Background data
In the 502 control groups finally included, the Infarct size
coefficient of variation were on average 28.9 ± 21.3%, with a
Table 4 Regression formula for hypothesis 3A
Regression formula for the effect of Occluding filament type on Infarct size coefficient of variation (hypothesis 3A)
Variable (reference category) Variable categories Regression coefficient 0.95 confidence interval for
regression coefficient
p-value
Constant NA 49.1 38.7 59.4 0.000
Occluding filament type (Uncoated) Silicon coated −12.7 −18.3 −7.0 0.000
Poly-L-Lysine coated 3.1 −4.8 11.0 0.444
Other coatings 3.1 −5.0 11.3 0.451
Strain (Sprague Dawley) Wistar −2.1 −8.3 4.1 0.507
SHR −3.0 −17.2 11.2 0.679
WKY 16.1 −5.6 37.8 0.146
Other Strains 25.9 11.0 40.7 0.001
Sex (Male) Female 3.3 −17.0 23.7 0.747
Ovx female 12.1 −8.5 32.6 0.248
Mix or not specified −5.0 −15.1 5.2 0.335
Elderly rats [Yes] −17.8 −38.4 2.9 0.091
Type of anesthetic (inhalation anesthetic) Chloral Hydrate −12.0 −18.7 −5.4 0.000
Ketamine 4.5 −4.3 13.2 0.315
Barbiturates and bensodiazepines −12.4 −24.8 0.00 0.050
Other anesthetic −14.2 −24.1 −4.4 0.005
Awakening of rats during occlusion (No) [Yes] 10.4 2.1 18.6 0.014
Temperature feedback system (No) [Yes] −7.6 −14.1 −1.2 0.021
Blood pressure monitored (No) [Yes] −12.0 −21.4 −2.6 0.013
Heart rate monitored (No) [Yes] 14.9 5.4 24.4 0.002
Blood gases/O2 saturation analyzed (No) [Yes] 11.5 1.8 21.1 0.021
Blood hemoglobin concentration
analyzed (No)
[Yes] 10.7 1.5 19.9 0.023
Occlusion duration (Short transient) Long transient −3.3 −9.3 2.8 0.288
Permanent −21.4 −30.1 −12.8 0.000
Time after focal ischemia for evaluation
of damage
[Continuous; Hours] 0.000036 −0.000013 0.000087 0.157
Blinding of infarct size determination
procedure (No)
[Yes] −3.8 −9.9 2.2 0.211
Criteria for excluding rats (None) Observed absence of cerebral blood flow
reduction
−7.4 −13.1 −1.7 0.011
Lack of functional deficit −5.6 −12.0 0.7 0.083
Too small infarct 7.6 −4.5 19.6 0.219
Other pathology in animal 16.2 8.7 23.6 0.000
Variables excluded by statistical software due to too low explanatory value: Weight, Intubation, Postoperative antibiotics, Blood glucose concentration analyzed,
Type of infarct size evaluation, Edema correction used.
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http://www.biomedcentral.com/1471-2202/14/41range from 1.7 to 148%. Mortality rate, the other outcome
variable, averaged 15.1 ± 13.5%, ranging from 0 to 60.4%.
The average number of animals in the 502 control
groups, which was used for weighing the studies’ impact
in the analyses, was 9.0 ± 7.7, with a range from 3 to 145.
Mean rat body weight in the included studies was 294.9 ±
61.0 g, ranging from group means of 190 to 779 g. Cere-
bral damage was evaluated on average 165.5 ± 506.3 hours
after ischemic insult, but this data was heavily skewed,with a median of 24 hours. The exclusion rate (due to
other reasons than mortality) averaged 8.9 ± 9.8% in the
few studies in which this information was available. Fre-
quencies of the different classifications in the registered
categorical variables are presented in Figure 5.
Discussion
The most important findings in the current hypothesis-
driven meta-analysis was that the Wistar strain and
Table 5 Regression formula for hypotheses 3B
Regression formula for the effect of Occluding filament type on Mortality rate (hypothesis 3B)
Variable (reference category) Variable categories Regression coefficient 0.95 confidence interval
for regression coefficient
p-value
Constant NA 16.8 13.2 20.4 0.000
Occluding filament type (Uncoated) Silicon coated −1.2 −4.7 2.4 0.516
Poly-L-Lysine coated 3.0 −1.3 7.4 0.171
Other coatings −3.6 −9.0 1.8 0.188
Type of anesthetic (Inhalation anesthetic) Chloral Hydrate 5.0 0.57 9.4 0.027
Ketamine 3.1 −1.6 7.8 0.198
Barbiturates and bensodiazepines 6.6 −0.91 14.1 0.085
Other anesthetic 5.6 −0.04 11.2 0.052
Awakening of rats during occlusion (No) [Yes] 9.7 4.5 14.8 0.000
Heart rate monitoring (No) [Yes] −6.5 −10.8 −2.2 0.003
Type of infarct size evaluation (TTC) Radiology 13.3 6.5 20.1 0.000
Acidic/Basic stain or silver stain histology −1.2 −5.2 2.9 0.576
Immunohistology 10.8 1.6 20.0 0.022
Criteria for excluding rats (None) Observed absence of cerebral blood flow
reduction
−5.5 −8.6 −2.4 0.001
Lack of functional deficit .39 −3.5 4.2 0.843
Too small infarct −7.4 −14.2 -.56 0.034
Other pathology in animal −1.2 −5.3 2.9 0.577
Variables excluded by statistical software due to too low explanatory value: Strain, Sex, Elderly rats, Weight, Intubation, Temperature feedback system, Blood
pressure monitoring, Blood gases/O2 saturation analyzed, Blood hemoglobin concentration analyzed, Blood glucose concentration analyzed, Postoperative
antibiotics, Occlusion duration, Time after focal ischemia for evaluation of damage, Edema correction used, Blinding of infarct size determination procedure.
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http://www.biomedcentral.com/1471-2202/14/41intraluminal filament procedure using a silicone coated
filament resulted in smallest infarct size variability. The
direct and endothelin methods rendered the lowest mortal-
ity rates, while the emboli method increased mortality when
compared to the intraluminal filament method. A number
of interesting observations regarding the control variables
were also made, such as the significant impact of the exclu-
sion criterion Observed absence of cerebral blood flow reduc-


































Figure 2 The choice of strain significantly affected the Infarct size coe
than Sprague Dawley, which was chosen as the reference category. Th
Dawley. Regarding mortality rate, the effects of animal strain was limited to
two analyses/graphs. The bars represent 0.95 confidence intervals.rats during occlusion on mortality (Table 3). However, since
these accidental findings were not part of the original hy-
pothesis, we refrain from drawing any conclusions about
them, and refer to Tables 2, 3, 4, 5 for the interested reader.
The high infarct size variability in rodent focal ische-
mic models is a problem that burdens the entire experi-
mental stroke field, and has been commented in several
reviews [2,362]. The problem with high outcome vari-
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fficient of variation, so that the Wistar rendered lower variability
e Other strains category increased variability in comparison to Sprague
a slight decrease from using SHR. N = 469 and 351, respectively, in the
































































Figure 3 Concerning Infarct size coefficient of variation, the general trend was that the intraluminal filament procedure, here chosen to
be the reference category, resulted in lower percentages than did the other methods. The emboli and endothelin injection methods
rendered significantly higher variability. Mortality rate was clearly influenced by choice of induction procedure, with higher percentages in the
emboli studies, while the direct and endothelin procedures had decreased numbers of deaths in comparison to the intraluminal filament
method. N = 469 and 351, respectively, in the two analyses/graphs. The bars represent 0.95 confidence intervals.
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http://www.biomedcentral.com/1471-2202/14/41get an adequate statistical power, which is problematic
from both an ethical and economical point of view. The
pressure from ethical boards on the researcher to
minimize the number of animals used may be the main
reason that the power of stroke experiments is often
low. In the current meta-analysis, the average infarct size
coefficient of variation was 28.9%, while the average
number of animals included in the control groups were
9.0. If we assume that the animals in the included stud-
ies often are equally distributed between the treatment
groups and control groups, these numbers can provide
an estimate of the average statistical power in the stud-
ies. Given the abovementioned numbers and an alpha of
0.05, the chance of detecting a 20% difference between
the groups would be merely 54.6% (if non-parametric
tests are used instead or if more than two groups are in-
cluded in the comparison, the power would be even
lower). Under these circumstances, a negative result is
marginally more interesting that tossing a coin. The use
of low power designs risks serious publication bias





























Figure 4 Silicone coated filaments rendered lower infarct size coeffici
and other filaments resulted in infarct size coefficients of variation comparable
choice of intraluminal filament type was seen. N = 383 and 265, respectively, istudies difficult to interpret properly, since there is prob-
ably an unknown number of unpublished studies that
cannot be weighed in. In addition to using means to de-
crease variability, it is of fundamental importance to use
a sufficient number of animals/replicates to render an
acceptably high power.
Mortality can be another confounding factor in experi-
mental stroke research, at least if it is not reported in
the article. With parametric statistical methods, incorp-
orating mortality in for example the infarct size calcula-
tions is not uncomplicated from a statistical point of
view, which is probably why the mortality is often simply
not mentioned. Non-parametric models may offer an al-
ternative approach [363], but irrespective of how the
main outcome is statistically assessed, the importance of
reporting mortality and other exclusion criteria cannot
be over-emphasized. For example, if mortality rate is
omitted, a substance that kills all rats with large infarcts
may seem to decrease infarct sizes, since only the ani-
mals with small infarcts will survive in the treatment


































ent of variation than the uncoated filaments. Poly-L-Lysine coated
to the uncoated counterparts. No effect on Mortality rate from the
n the two analyses/graphs. The bars represent 0.95 confidence intervals.
Figure 5 Frequencies of registered categories in the 502 included control groups. The specific exclusion criteria are presented separately in
the last 4 bars. Many of the variable names are abbreviated in the figure; for extended description, see Table 1. “Histology” in the bar “Type of
infarct evaluation” refers to acidic/basic stain or silver stain histology. EEG = Electroencephalography, B = Blood, Hb = Hemoglobin.
Ström et al. BMC Neuroscience 2013, 14:41 Page 12 of 24
http://www.biomedcentral.com/1471-2202/14/41
Ström et al. BMC Neuroscience 2013, 14:41 Page 13 of 24
http://www.biomedcentral.com/1471-2202/14/41reported in experimental stroke studies. In fact, for only
35.3% of the included control groups an account of un-
intended deaths was provided; and this was the most fre-
quently requested item in our e-mail correspondence.
A few previous studies have assessed the influence of
the rat strain on experimental stroke outcomes, however
with conflicting results. Spontaneously hypertensive rats
(SHR) have, probably because of the implications of hyper-
tension in stroke pathophysiology, attracted some atten-
tion. Since this strain often sustains larger infarcts [364],
the infarct size coefficient of variation has in a few studies
been shown to be relatively low [8,365,366]. Others have
argued that the use of another inbred strain – Fischer-344
rats – give the most consistent results [7,367,368], how-
ever this type may because of its variable vascular anatomy
be unsuitable for the well-used intraluminal filament
model [369]. Long Evans rats have also been proponed as
a good model animal, because of the relatively consistent
decrease in cerebral blood flow after intraluminal filament
MCAo [370]. Many other studies have investigated differ-
ences between rat strains, however not focusing on vari-
ability, but rather on infarct sizes per se [371-373]. Except
for the study emphasizing the unsuitability of Fischer-344
for intraluminal filament MCAo [369], we are only aware
of one study aiming to compare mortality between strains.
In this study, an intraluminal filament model rendered
higher mortality in Fischer-344 rats than in Wistar and
Sprague–Dawley rats [7]. It is not easy to summarize the
conclusions in the existing literature, since the mentioned
experiments have been performed under such different
circumstances, but it seems that SHR might be attractive
because of their low variability. In the current meta-
analysis, there was a slight trend towards lower variability
in the SHR strain compared to the reference category
Sprague–Dawley, which however was far from reaching
statistical significance. Regarding Long Evans and Fischer-
344, these strains were used too rarely to be analyzed sep-
arately. As abovementioned, the strain that we found to
render the lowest variability was the relatively well-used
Wistar strain.
Very few studies have compared different methods of in-
ducing focal cerebral ischemia. This is perhaps not surpris-
ing given that the effort of introducing an entirely new
MCAo method in a laboratory is large enough to make
many researchers reluctant to switch once a technique has
been mastered. This lack of relevant studies underscores
the importance of a meta-analysis as the current one.
However, in a study by Gerriets et al. [10], an embolization
technique was compared to an intraluminal filament pro-
cedure. The take-home message from that article was that
even though infarct variability tended to be higher from
the emboli method, as corroborated by the current study,
it did not affect body temperature to the same extent as
the filament method did. In another article, the use ofmicrosurgical direct occlusion was advocated over the
intraluminal filament method because the latter was
thought to not only compromise blood flow to the MCA
territory, but rather a larger part of the ICA territory [374].
Different types of filaments for the intraluminal method
are much easier to compare, and have been assessed in sev-
eral studies. Most of these studies have argued that silicone
coated rather than uncoated or poly-L-lysine coated fila-
ments should be used, because of a more consistent blood
flow reduction [375], lower incidence of sub-arachnoid
hemorrhage [14,376], higher success rate [376-378], lower
mortality [377] and lower variability [368,376], even if argu-
ments based on low variability also have been used to en-
courage the use of poly-L-lysine coating [379]. In the
current analysis, it was found that silicone coated filaments
are superior in terms of reducing infarct size variability,
while no effects on mortality were found. Another study
compared different brands of blunted nylon filaments, and
found Ethilon to be superior to Nitcho [380].
Strengths and weaknesses
The main strength of the current study is that it, based
on hundreds of published studies, provides a composite
understanding of how different methodological factors
interact to affect outcome variability and mortality.
However, since this method-investigating meta-analytical
approach is relatively novel, we consider it important to
highlight and discuss some aspects of the design:
 A multiple regression analysis assumes that the
variables are linearly related, which evidently is not
always true. For example, the effect of average body
weight on variability could theoretically be U-shaped,
with higher variability in young, not fully developed,
rats and very old animals, than in adult animals. This
is an inherent drawback, but multiple regression
analysis still seemed the most attractive statistical
method for the current purpose.
 There is a problem in investigating coefficients of
variation in published studies, and weighing the
impact of the included control groups by number of
animals, since important sources of bias come into
play. Researchers that know that their model render
large variability will compensate by including more
animals, thus giving more weight in the meta-
analysis to studies with larger variability. We
however believe that weighing the analysis by
number of animals is the fairest alternative. Another
problem is publication bias, since the studies
rendering the largest coefficients of variation
probably to large part remain unpublished, and
cannot be assessed.
 Even if this meta-analysis controls for many
confounders by its broad approach, there is
Ström et al. BMC Neuroscience 2013, 14:41 Page 14 of 24
http://www.biomedcentral.com/1471-2202/14/41complexity and heterogeneity in the underlying
experiments that is far beyond our reach. For
example, the impact of different rat vendors [381],
the skill of the surgeon and the suitability of using
specific rat strains for certain surgical procedures
are not accounted for. For mathematical reasons,
categories have also, as stated in the Materials and
Methods section, been reduced to larger categories,
meaning that differences within categories may be
lost. There are for example numerous variations
within the different MCAo techniques, and it is
likely that the best embolization procedure renders a
lower variability than the worst intraluminal
filament paradigm, even if the last-mentioned
method proved superior on a general level.
 The meta-analysis includes 502 control groups from
only 346 published reports, meaning that several
studies described more than one control group. We
have in the statistical analysis regarded control
groups from the same study as independent, which
is not statistically stringent. However, if categories
had been created for all separate studies, the entire
analysis would have been impossible to perform, and
thus this imperfection is an inevitable problem with
the chosen approach.
Conclusions
The choice of methodological parameters, such as rat
strain and infarct surgical procedures, is of utmost im-
portance for consistent and reliable results. As found in
the meta-analysis, the effect sizes were large, with many
parameters by themselves increasing or decreasing vari-
ability and mortality with more than 10% (in absolute
terms).
Finally, it deserves to be emphasized that this analysis
does not encompass all perspectives on the suitability of
focal stroke models. Even if infarct size coefficient of
variation and mortality are important components, other
aspects, not least similarity of the model to the clinical
situation, emphasizing the importance of the embolic
model [382], must be taken into consideration when
planning experiments.
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